- Published at
- by gurufocus.com
mixed
mixed
Notice of Nominees for Directors
PR NewswireTOKYO, May 7, 2025
TOKYO, May 7, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today annou
News for Proteostasis Therapeutics Inc (PTI)
- Published at
- by investing.com
mixedmixedHarness Therapeutics Appoints Seasoned Biopharmaceutical Leader, Ms. Meenu Chhabra Karson, as Board Chair By Investing.com
Harness Therapeutics Appoints Seasoned Biopharmaceutical Leader, Ms. Meenu Chhabra Karson, as Board Chair- Published at
- by marijuanastocks.com
neutralneutral- Published at
- by globenewswire.com
neutralneutral- Published at
- by globenewswire.com
mixedmixedKineta Expands Board of Directors with Biotech Industry Leaders Kim Drapkin and Scott Dylla
SEATTLE, June 28, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel...- Published at
- by marketscreener.com
mixedmixedYumanity Therapeutics : January 2023 Developing next-generation immunotherapies that address cancer immune resistance KA (Nasdaq) - Form 8-K
January 2023 Developing next-generation immunotherapies that address cancer immune resistance KA Disclaimers and other information Cautionary... | January 5, 2023- Published at
- by globenewswire.com
mixedmixedMacroGenics Announces Appointment of Dr. Margaret Liu and Meenu Chhabra Karson to Board of Directors
ROCKVILLE, MD, Jan. 04, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing...- Published at
- by globenewswire.com
mixedmixed- Published at
- by etfdailynews.com
positivepositiveYumanity Therapeutics (NASDAQ:YMTX) Lowered to “Hold” at Zacks Investment Research
Read Yumanity Therapeutics (NASDAQ:YMTX) Lowered to “Hold” at Zacks Investment Research at ETF Daily News- Published at
- by globenewswire.com
positivepositiveVallon Pharmaceuticals Announces Appointment of Meenu Karson to Board of Directors
Global biopharmaceutical industry senior executive with over 15 years of operational leadership with transactional and capital markets experience spanning...- Published at
- by etfdailynews.com
mixedmixedYumanity Therapeutics (NASDAQ:YMTX) Raised to “Buy” at Zacks Investment Research
Zacks Investment Research upgraded shares of Yumanity Therapeutics (NASDAQ:YMTX) from a hold rating to a buy rating in a report released on Tuesday morning, Zacks.com reports. Zacks Investment Research currently has $3.00 target price on the stock. According to Zacks, “Yumanity Therapeutics Inc. is a clinical-stage biopharmaceutical company involved in the treatment of neurodegenerative diseases. […]